Forskning ved Københavns Universitet - Københavns Universitet

Forside

Biologiske lægemidler til behandling af ikke-cancerrelaterede sygdommeTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • L. Skov
  • K. Bendtzen
Biological response modifiers are modified (poly) peptides from living organisms designed to modulate a specific biologic process. Biotechnology has led to the rapid development of recombinant drugs for treatment of many immunoinflammatory diseases. In this article, we briefly describe the main types of these therapeutic proteins, their mechanisms of action and side-effects
Udgivelsesdato: 2008/6/9
OriginalsprogDansk
TidsskriftUgeskrift for læger
Vol/bind170
Udgave nummer24
Sider (fra-til)2120-2126
Antal sider6
ISSN0041-5782
StatusUdgivet - 2008

ID: 10213839